Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01092923




Registration number
NCT01092923
Ethics application status
Date submitted
10/03/2010
Date registered
25/03/2010
Date last updated
12/10/2012

Titles & IDs
Public title
Physiological Effects of Nitrous Oxide on Anaesthesia
Scientific title
Nitrous Oxide and Inhalational Agent Pharmacokinetics During Anaesthetic Induction and Emergence
Secondary ID [1] 0 0
03749
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anesthesia 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - sevoflurane on air/O2
Treatment: Drugs - sevoflurane in N2O/O2

Experimental: Air/Oxygen - Sevoflurane with Air/Oxygen Mix

Experimental: sevoflurane in N2O/O2 -


Treatment: Drugs: sevoflurane on air/O2
sevoflurane on air/O2

Treatment: Drugs: sevoflurane in N2O/O2
sevoflurane in N2O/O2
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)
Timepoint [1] 0 0
Baseline, 2 minutes, 5 minutes, and 30 minutes after emergence
Primary outcome [2] 0 0
PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)
Timepoint [2] 0 0
Baseline, 2 minutes, and 5 minutes after emergence
Secondary outcome [1] 0 0
Time to Eye Opening
Timepoint [1] 0 0
20 Minutes

Eligibility
Key inclusion criteria
- Adult patients undergoing elective general or orthopaedic surgery under relaxant
general anaesthesia anticipated to take >1 hour
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Age under 18 years

- Morbid obesity BMI > 35

- Severe or moderately severe lung disease (FEV1 < 1.0L, FEV1/FVC < 50%)

- Past history of severe post-operative nausea and vomiting

- Pregnancy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2010
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Austin Health - Melbourne
Recruitment postcode(s) [1] 0 0
3084 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Austin Health
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Nitrous oxide is the oldest anaesthetic agent still in routine use today. Despite huge
changes in the pharmacology of volatile anaesthetic agents and intravenous anaesthetics, the
unique properties of nitrous oxide have maintained its place in modern practice, where it is
used in combination with other, more powerful inhaled agents, such as sevoflurane. It has
useful analgesic properties, unlike the other agents used today, and its inclusion reduces
the concentration of other agents required to maintain an adequate depth of anaesthesia for
surgery.

In particular, its low solubility in body tissues gives it a unique pharmacokinetic profile,
with rapid washin and washout from the body. It has been shown to have a similar effect on
the speed of uptake of accompanying agents like sevoflurane (the "second gas effect"), which
have much slower pharmacokinetics. A recent study by us suggested that this promotes faster
and smoother onset of anaesthesia, as measured using the standard monitor of depth of
anaesthesia (the BIS monitor). This finding requires confirmation prospectively in a larger
group of patients. The investigators further hypothesise that a similar effect also exists on
washout of sevoflurane at the end of the procedure, promoting quicker recovery (emergence)
from anaesthesia. This has never been previously demonstrated. This information will help
better define the place of nitrous oxide in achieving optimal outcomes in modern anaesthetic
practice. The investigators propose to conduct a simple study to measure the effects of
nitrous oxide washin and washout on exhaled concentrations of accompanying sevoflurane during
both induction of anaesthesia and emergence, and identify any accompanying effect on the rate
of change in depth of anaesthesia using BIS. The investigators hypothesise that the rate of
fall of exhaled sevoflurane concentration at the end of anaesthesia will be more rapid in the
group of patients breathing a gas mixture containing nitrous oxide, and that the rate of fall
of BIS on induction and the rate of rise of BIS on emergence will be faster in the nitrous
oxide group.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01092923
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Phil Peyton, MBBS
Address 0 0
Austin Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01092923